These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7034817)

  • 1. The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (Factor IX) concentrates in rabbits.
    Giles AR; Nesheim ME; Hoogendoorn H; Tracy PB; Mann KG
    Blood; 1982 Feb; 59(2):401-7. PubMed ID: 7034817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stroma free human platelet lysates potentiate the in vivo thrombogenicity of factor Xa by the provision of coagulant-active phospholipid.
    Giles AR; Nesheim ME; Hoogendoorn H; Tracy PB; Mann KG
    Br J Haematol; 1982 Jul; 51(3):457-68. PubMed ID: 7104230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro thrombogenicity tests of factor IX concentrates. II: effects of phospholipids and heparin.
    Prowse CV; Boffa MC; Guthrie C; Pepper DS
    Thromb Haemost; 1980 Feb; 42(5):1368-77. PubMed ID: 7368144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo.
    Giles AR; Mann KG; Nesheim ME
    Br J Haematol; 1988 Aug; 69(4):491-7. PubMed ID: 3136794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prothrombin contributes to the assembly of the factor Va-factor Xa complex at phosphatidylserine-containing phospholipid membranes.
    Billy D; Willems GM; Hemker HC; Lindhout T
    J Biol Chem; 1995 Nov; 270(45):26883-9. PubMed ID: 7592932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction, expression, and characterization of a chimera of factor IX and factor X. The role of the second epidermal growth factor domain and serine protease domain in factor Va binding.
    Hertzberg MS; Ben-Tal O; Furie B; Furie BC
    J Biol Chem; 1992 Jul; 267(21):14759-66. PubMed ID: 1634519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombogenicity of factor IX complex: in vivo investigation.
    Aronson DL; Menache D
    Dev Biol Stand; 1987; 67():149-55. PubMed ID: 3609475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bothrojaracin, a proexosite I ligand, inhibits factor Va-accelerated prothrombin activation.
    Monteiro RQ; Zingali RB
    Thromb Haemost; 2002 Feb; 87(2):288-93. PubMed ID: 11858489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meizothrombin formation during factor Xa-catalyzed prothrombin activation. Formation in a purified system and in plasma.
    Tans G; Janssen-Claessen T; Hemker HC; Zwaal RF; Rosing J
    J Biol Chem; 1991 Nov; 266(32):21864-73. PubMed ID: 1939210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of phospholipids and factor Va in the prothrombinase complex.
    Rosing J; Tans G; Govers-Riemslag JW; Zwaal RF; Hemker HC
    J Biol Chem; 1980 Jan; 255(1):274-83. PubMed ID: 7350159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apparent intrinsic prothrombinase activity of human Factor X zymogen: identification with Factor VIII inhibitor bypassing activity (FEIBA).
    Estry DW; Tishkoff GH
    Thromb Res; 1984 Dec; 36(6):549-62. PubMed ID: 6335607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The thrombogenicity of prothrombin complex concentrates. IV. The source of coagulant-active phospholipid.
    Giles AR; Hoogendoorn H; Tinlin S
    Thromb Res; 1984 Jun; 34(6):567-72. PubMed ID: 6740574
    [No Abstract]   [Full Text] [Related]  

  • 13. The contribution of bovine Factor V and Factor Va to the activity of prothrombinase.
    Nesheim ME; Taswell JB; Mann KG
    J Biol Chem; 1979 Nov; 254(21):10952-62. PubMed ID: 500617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assembly of the prothrombinase complex on lipid vesicles depends on the stereochemical configuration of the polar headgroup of phosphatidylserine.
    Comfurius P; Smeets EF; Willems GM; Bevers EM; Zwaal RF
    Biochemistry; 1994 Aug; 33(34):10319-24. PubMed ID: 8068668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of the formation and activity of factor V-phospholipid complexes. I. Influence of phospholipid structure.
    Kandall CL; Shohet SB; Akinbami TK; Colman RW
    Thromb Diath Haemorrh; 1975 Sep; 34(1):256-70. PubMed ID: 1237944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo.
    White GC; Roberts HR; Kingdon HS; Lundblad RL
    Blood; 1977 Feb; 49(2):159-70. PubMed ID: 12845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The thrombogenicity of prothrombin complex concentrates: II. The effect of thrombocytopenia on in vivo thrombogenicity in rabbits.
    Giles AR; Hoogendoorn H; Blajchman MA; Hirsh J
    Thromb Res; 1980 Feb 1-15; 17(3-4):555-60. PubMed ID: 7368174
    [No Abstract]   [Full Text] [Related]  

  • 18. A membrane-mediated catalytic event in prothrombin activation.
    Kung C; Hayes E; Mann KG
    J Biol Chem; 1994 Oct; 269(41):25838-48. PubMed ID: 7929289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prothrombin activation on dioleoylphosphatidylcholine membranes.
    Govers-Riemslag JW; Janssen MP; Zwaal RF; Rosing J
    Eur J Biochem; 1994 Feb; 220(1):131-8. PubMed ID: 8119280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prothrombin activation by prothrombinase in a tubular flow reactor.
    Billy D; Speijer H; Willems G; Hemker HC; Lindhout T
    J Biol Chem; 1995 Jan; 270(3):1029-34. PubMed ID: 7836355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.